Dr. Baumann Kreuziger specializes in non-malignant hematology with an emphasis on patients with clotting and bleeding disorders.  Dr. Baumann Kreuziger is interested in the underlying mechanisms of thrombosis and optimal treatment strategies for patients with thrombosis.

She leads the Venous thromboEmbolism Network United States (VENUS). More information can be found here: https://www.venusresearch.org.

• ACTIV-4 Clinical Trial Platforms
• American Society of Hematology
• Recipient Epidemiology and Donor Evaluation Study IV (REDS IV-P) (co PI-Mast)
• INVENT Kickstarter Award

For a full list of Dr. Baumann Kreuziger's publications Click Here (Redirects to NCBI).

Selected Publications

• COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/
• Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, ……Cushman M, Jüni P; RAPID trial investigators. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021 Oct 14;375:n2400. doi: 10.1136/bmj.n2400. PMID: 34649864; PMCID: PMC8515466
• ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, ….Baumann Kreuziger L…., Farkouh ME, Hochman JS, Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. NEJM/New England Journal of Medicine. 2021 Aug 4. doi: 10.1056/NEJMoa2105911.
• Baumann Kreuziger L, Feng M, Bartosic A, Simpson P, Wang TF. A prospective cohort study of catheter-related thrombosis in cancer patients treated with 1 month of anticoagulation after catheter removal. Blood Coagul Fibrinolysis. 2022 Jan 3. doi: 10.1097/MBC.0000000000001122. Epub ahead of print. PMID: 34980834.
• Held N, Jung B, Baumann Kreuziger L. Management of cancer-associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement. Res Pract Thromb Haemost. 2022 May 25;6(4):e12726. doi: 10.1002/rth2.12726. PMID: 35664532; PMCID: PMC9133434.
• Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ, Huisman MV, Kearon C, King CS, Knighton AJ, Lake E, Murin S, Vintch JRE, Wells PS, Moores LK. Antithrombotic Therapy for VTE Disease: Second Update of the CHESTGuideline and Expert Panel Report – Executive Summary, CHEST (2021), doi: https://doi.org/10.1016/j.chest.2021.07.056.
• Kreuziger LB, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Jaglal M, Houghton DE, Streiff MB, Gali R, Feng M, Simpson P, Billett HH. Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thromb Res. 2021 Jun;2020:155-161. doi: 10.1016/j.thromres.2021.03.021. Epub 2021 Apr 6. PMID: 33862470.
• Houghton DE, Billett HH, Gaddh M, Onadeko O, George G, Wang TF, Oo TH, Feng M, Dasgupta M, Jaglal M, Streiff MB, Simpson P, Gali R, Baumann Kreuziger L. Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Adv. 2021 Jul 27;5(14):2807-2812. doi: 10.1182/bloodadvances.2021004698. PMID: 34264267. 
• Kreuziger LB, Edgren G, Hauser RG, Zaccaro D, Kiss J, Westlake M, Brambilla D, Mast AE. Red Blood Transfusion Does Not Increase Risk of Venous or Arterial Thrombosis. Am J Hematol. 2021 Feb 1;96(2):218-225. doi: 10.1002/ajh.26038. Epub 2020 Nov 16.
• Rosovsky RP, Sanfilippo KM, Wang TF, Rajan SK, Shah S, Martin KA, Ni Ainle F, Huisman M, Hunt BJ, Khan SR, Kevane B, Lee AYY, McLintok C, Kreuziger LB. Anticoagulation Practice Patterns in COVID‐19: A Global Survey. Res Prac Thromb Haemost. 2020 Jul 9;4(6):969-83. doi:10.1002/rth2.12414
• Held N, Jung B, Sommervold L, Sing S, Kreuziger LB.  Patient safety indicator-12 rarely identifies problems with quality of care in perioperative venous thromboembolism. J Hosp Med. 2019 Nov 20;14:E1-E6. PMID: 31995470